Metabolic labeling of glycans with bioorthogonal reporters has been widely used for glycan imaging and glycoproteomic profiling. One of the intrinsic limitations of metabolic glycan labeling is the lack of cell-type selectivity. The recently developed liposome-assisted bioorthogonal reporter (LABOR) strategy provides a promising means to overcome this limitation, but the mechanism of LABOR has not been investigated in detail. In this work, we performed a mechanistic study on LABOR and explored its multiplexing capability. Our studies support an endocytosis-salvage mechanism. The ligand-targeted liposomes encapsulating azidosugars are internalized into the endosome via the receptor-mediated endocytosis. Unlike the conventional drug delivery, LABOR does not rely on the endosomal escape pathways. Rather, the liposomes are allowed to enter the lysosome, inside which the azidosugars are released from the liposomes.
INTRODUCTION
Cells uptake monosaccharides, which serve as precursors for the biosynthesis of glycans in various glycoconjugates, including glycoproteins, glycolipids, and proteoglycans. Glycans play essential roles in regulating diverse biological and pathological processes. 1 The metabolic machinery can be harnessed to incorporate exogenous monosaccharide analogs or unnatural sugars bearing a bioorthogonal functional group (e.g., the azide or alkyne) into cellular glycans. [2] [3] [4] The incorporated azide or alkyne serves as a chemical handle for subsequent chemoselective conjugation with biophysical probes (e.g., fluorophores or affinity tags) functionalized with a complementary bioorthogonal group. Termed metabolic glycan labeling (MGL) or metabolic oligosaccharide engineering (MOE), this two-step chemical reporter strategy has emerged as a powerful tool for probing sialylation, [5] [6] [7] [8] [9] mucin-type O-linked glycosylation, [10] [11] [12] fucosylation, [13] [14] [15] [16] and OGlcNAcyaltion [17] [18] [19] [20] [21] in live cells and in living animals.
Unnatural sugars usually enter cells without discriminating cell types, resulting in global labeling of glycans in various cell types. The lack of cell-type selectivity hampers the utility of MGL in profiling glycosylation of specific cell types within a complex biological system. 22 To overcome this limitation, we recently developed a liposome-assisted strategy for selective labeling of glycans in specific cell types. 23 This strategy utilizes the ligand-targeted liposomes to encapsulate azidosugars and deliver them into the target cells via specific ligand-receptor recognition. The delivered azidosugars are metabolically incorporated into cellular glycans and the resulting azide-incorporated glycans are then labeled with desired probes using bioorthogonal chemistry. Furthermore, it was demonstrated that this strategy could be used to label and visualize tumor-associated sialoglycans and brain sialoglycans in living mice. 24, 25 Termed the LABOR (liposome-assisted bioorthogonal reporter) strategy, this technique has expanded the utility of 4 MGL and enabled many potential applications. For example, it is of great interest to label glycans in a specific cell type when studying how glycans regulate cell-cell interactions, so that the origin of the labeled glycans is not obscured by surrounding cells sharing the common glycan structures.
In addition, metabolic labeling of low-abundance glycans or glycans in low-abundance cells can tremendously benefit from cell-type selectivity.
Towards realizing those applications, we herein report the mechanistic investigation of LABOR and the exploration of its multiplexing capability. By using the ligand-targeted liposomes encapsulating 9AzSia, an azido analog of sialic acid (Sia), our studies support an endocytosissalvage mechanism of LABOR ( Figure 1 ). The liposomes are internalized into the endosome via the receptor-mediated endocytosis and then traffic to the lysosome, inside which 9AzSia is released out of the liposomes. The released 9AzSia intercepts the salvage pathway of Sia, and gets transported out of the lysosome to the cytoplasm by the lysosomal transporter sialin (SLC17A5), located on the lysosome membrane. Based on this mechanism, we performed a comprehensive evaluation of the scope of LABOR. A panel of ligand-receptor pairs were evaluated to target azidosugars to distinct cell types for cell-selective MGL. Finally, we demonstrated that LABOR could be used to simultaneously label two cell populations with two distinct chemical reporters.
5 Sia transporter sialin on the lysosome then transports 9AzSia into the cytoplasm, where it enters the Sia biosynthetic pathway and gets incorporated into the cell-surface sialoglycans.
RESULTS AND DISCUSSION

Azidosugar-encapsulated ligand-targeted liposomes enter cells via receptor-mediated
endocytosis. In MGL, azido or alkynyl analogs of ManNAc or Sia enter the de novo biosynthesis of Sia and are eventually incorporated into sialoglycans ( Figure 1 and SI, Figure S1 ). Besides de novo biosynthesis, cells also recycle Sia from degraded sialoglycoconjugates (e.g., sialylated
proteins and lipids) via the Sia salvage pathway, in which the lysosomal sialidases release Sia from sialoglycoconjugates (SI, Figure S1 ). The free Sia is then transported into the cytoplasm by the 23 as a model system.
The targeted drug delivery and gene delivery using ligand-targeted liposomes have been extensively studied and the drug-encapsulated liposomes are commonly reported to enter the cells via the receptor-mediated endocytosis. 27 For example, it was shown that the drug-loaded liposomes functionalized with FA on the surface, upon binding to the cell-surface folate receptor (FR), were efficiently internalized into endosomes via FR-mediated endocytosis, and subsequently released the drug into the cytosol. 28 To investigate whether f-LP-9AzSia enters the cells via the receptor-mediated endocytosis, we assayed its co-localization with the endosome and lysosome.
The f-LP-9AzSia was fluorescently labeled with the lipophilic dye DiI, which did not significantly alter the liposome diameter or the 9AzSia encapsulation efficiency (SI, Table S1 ). The FR + HeLa cells (i.e., HeLa cells with the expression of FR upregulated by culturing in FA-depleted media)
were treated with DiI-labeled f-LP-9AzSia for 0.5 h, and confocal fluorescence microscopy showed binding of f/DiI-LP-9AzSia onto the cell surfaces ( Figure 2A ). Starting from 3 h, f/DiI-LP-9AzSia formed many intracellular puncta, which exhibited colocalization with the LysoTracker Deep Red, a live-cell indicator of lysosomes ( Figure 2B , C). At 24 h, f/DiI-LP-9AzSia on the membrane had been completely internalized into the lysosomes ( Figure 2D ). By contrast, DiI-LP9AzSia showed minimal binding to FR + HeLa cells and no translocation to the lysosome, demonstrating that the FA-FR recognition was essential for liposome uptake ( Figure 2E -H).
To evaluate the colocalization of f/DiI-LP-9AzSia with the endosome, the liposome-treated cells were fixed, permeabilized, and stained with an early endosome antigen 1 (EEA1) antibody 7 ( Figure 3 ). Partial cocolocalizaiton of f/DiI-LP-9AzSia with EEA1 was observed as early as 1.5
h. Under the fixed cell condition, we also observed similar colocalization of f/DiI-LP-9AzSia with the lysosome, as stained by a lysosomal associated membrane protein 1 (LAMP1) antibody (SI, Figure S2 ). These results indicate that f/DiI-LP-9AzSia traffic into the early endosome and lysosome successively after internalization via the FR-mediated endocytosis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 After f/DiI-LP-9AzSia translocated into the lysosome, 9AzSia was eventually incorporated into cell-surface sialoglycans, as shown by reacting the cells with alkyne-biotin and staining with streptavidin-Alexa Fluor 647 (AF647) at 24 h (SI, Figure S3 ). Since Sia is de novo biosynthesized in the cytosol before being transported into the nucleus and converted to CMP-Sia (SI, Figure S1 ), 9AzSia needs to get out of the liposome and then the lysosome. To track the intracellular release of liposome-encapsulated molecules in the lysosomes, we loaded LPs with calcein at 300 mM, a 9 concentration at which the fluorescence of calcein is self-quenched. 29 Once being released out of the liposome, the calcein fluorescence is turned on due to dilution. In the aqueous solution, LPcalcein was relatively stable at pH 7.4 for up to 24 h (SI, Figure S4 ). Lowering the pH resulted in release of calcein. At pH 4.5 to 5.0, the pH of the interior of lysosomes, about 5%~10% release was observed at 24 h. Moreover, the enzymes inside the lysosome are capable of degrading the liposomal membrane. 30 When the FR + HeLa cells were treated with f/DiI-LP-calcein, only DiI fluorescence was observed on the cell surface ( Figure 4A) . From 3 h, the release of calcein into Sialin can transport 9AzSia from the lysosome into the cytosol. The lysosomal Sia transporter sialin is responsible for the export of free Sia from the lysosome. Cells can uptake Sia via fluid phase pinocytosis, a clathrin-independent endocytic pathway. 31 The negatively charged Sia is restricted from passive diffusion out of the endosome and reaches the lysosome, where it is then transported to the cytosol by sialin (SI, Figure S1 ). Sialin was also reported to transport N-(4-pentynoyl)neuramic acid (SiaNAl), an alkynyl analog of Sia. 32 To test whether 9AzSia could be transported by sialin, we fed 9AzSia to FR + HeLa cells overexpressing EGFP-sialin and the wild-type (WT) cells (SI, Figure S5 ). Presumably, 9AzSia was internalized into the lysosome via fluid phase pinocytosis. Flow cytometry analysis on cells reacted with DBCO-biotin and stained with streptavidin-AF647 showed increased labeling on sialin-overexpressed cells at various concentrations of 9AzSia, indicating that 9AzSia metabolism was dependent on sialin ( Figure 5A ).
The sialin-overexpressed cells were then treated with f-LP-9AzSia at concentrations ranging from 10 µM to 500 µM. Increased 9AzSia incorporation was observed for all f-LP-9AzSia
concentrations, comparing to the FR + HeLa cells with no sialin overexpression ( Figure 5B ).
Increased 9AzSia incorporation, to a less extend, was observed by treating the cells with LP9AzSia ( Figure 5C ). Notably, overexpression of sialin should also increase the transport of recycled Sia into the cytosol and thus competing the incorporation of 9Azsia into sialoglycans.
Nevertheless, these data demonstrate that sialin is capable of pumping 9AzSia into the cytosol 11 from the lysosome and LABOR exploits the receptor-mediated endocytosis and the salvage pathway to metabolically label glycans with cell selectivity. Trastuzumab (Herceptin) is a monoclonal antibody specific for the human epidermal growth factor receptor-2 (HER2), which is overexpressed in certain types of breast cancer. 33 To prepare HER2-targeting liposomes encapsulating 9AzSia (tras-LP-9AzSia), trastuzumab was thiolated using 2-iminothiolane and subsequently conjugated to the maleimide-functionalized liposomes (SI , Table S1 ). Sgc8 is a 42-base aptamer that has high specificity and affinity for protein tyrosine kinase-7 (PTK7) on leukemia cell surfaces. 34 Sgc8-LP-9AzSia was prepared by conjugating the 3′-thiol-modified Sgc8 aptamer with the maleimide-functionalized liposomes (SI, Table S1 ).
BPC NeuAc (9-N-biphenylcarboxyl-NeuAcα2,6Galβ1,4GlcNAc; SI, Figure S6A ) and POB NeuAc (9-N-phenoxybenzamido-NeuAcα2,6Galβ1,4GlcNAc; SI, Figure S6B ) are two synthetic high affinity glycan ligands of human CD22 (siglec-2). 35, 36 As a B-lymphocyte-specific receptor, CD22 is a member of the sialic acid binding Ig-like lectin (Siglec) family and recognizes sialosides containing α2,6-linked sialic acids. 37 NeuAc-LP-9AzSia; SI, Table S1 ). The RGD peptide can serve as a ligand for αVβ3
integrin. 39 RGD-LP-9AzSia was prepared using a procedure adapted from the previous report (SI, Table S1 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 16 Furthermore, the co-culture of hCD22_CHO and WT CHO cells was treated with 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 addition, cell-selective labeling of sialoglycans was demonstrated for Sgc8-LP-Sia9Az (SI, Figure S9 ) and RGD-LP-Sia9Az (SI, Figure S10 ). It is of note that the selectivity could dependent on the binding affinity between the ligand-receptor pairs and the cell types. Taken 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 18 similar labeling was observed in two cell populations when treated with LP-9AzSia or 9AzSia.
These results indicate that Figure 10A ). We chose alkyne-functionalized sialic acid, SiaNAl, as a second reporter for sialoglycans. The K20 cells were incubated with SiaNAl, reacted with with azide-AF647 via copper(I)-catalyzed alkyne-azide cycloadditions (CuAAC) assisted with the BTTAA ligand. 41 Flow cytometry analysis showed the incorporation of SiaNAl into K20 cellsurface glycans in a dose-dependent manner (SI, Figure S12 ). We then prepared BPC NeuAc-LPSiaNAl using a similar procedure (SI, Table S1 ) and confirmed that BPC NeuAc-LP-SiaNAl could be used for targeted labeling of sialoglycans in K20 cells (SI, Figure S13 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 21 chemical reporters for glycans cannot be controlled by cell-specific promoters. 22 The endocytosis-salvage mechanism of LABOR provides guidelines for future development and applications of LABOR. Regarding the compatibility of unnatural sugars with LABOR, one should probably explore those that can be transported by the lysosomal transporters. 44 For example, GlcNAc and GalNAc could be transported to the cytosol after glycoprotein degradation in lysosomes, 45 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   22 solution to this limitation is to explore liposomes that can fuse with the cell membrane and thus deliver the cargo directly into the cytosol. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 For preparation of trastuzumab-functionalized liposomes, trastuzumab (1 eq) was thiolated by 2-iminothiolane (100 eq) at 4 ºC for 1 h. The thiolated trastuzumab (1 eq) was mixed with the purified liposomes containing Mal-PEG-DSPE (10 eq), and incubated at 4 ºC overnight, followed by gel filtration through Sepharose CL-4B (GE Healthcare) to remove the unconjugated trastuzumab. For preparation of Sgc8-functionalized liposomes, the 5′-thiol-modified Sgc8 aptamer was first activated by 100 mM TCEP at 4 ºC for 30 min and the resulting aptamer (5 eq) was incubated with liposomes containing Mal-PEG-DSPE (1 eq) overnight, followed by removing the unconjugated Sgc8 by Sephadex-G50.
The diameters of the prepared liposomes were measured using dynamic light scattering 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   27 imaging. Fluorescence microscopy was performed on a Zeiss LSM 700 laser scanning confocal microscope.
For multiplexed LABOR, FR + HeLa and K20 cells were transferred into a V-bottom 96-well plate and rinsed with 1% FBS-PBS. First, the azides were labeled with 50 µM DBCOCarboxyrhodamine 110 in 0.5% FBS-PBS for 15 min at RT. After washing with 1% FBS-PBS for three times, the cells were treated with 50 mM TCEP for 10 min to reduce the unreacted azides.
Next, the alkynes were labeled via CuAAC in 0.5% FBS-PBS containing 50 µM azido-AF647, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 28 AF488 (Invitrogen) at RT for 1 h. After staining the nuclei with 5 µg/mL Hoechst 33342 for 10 min, the cells were subjected to confocal fluorescence imaging.
Sialin Expression Regulation. The amino-terminus of sialin was fused to GFP by subcloning at the EcoRI and XmaI sites of the pEGFP-C1 vector (Clontech). FR + HeLa cells were transfected by electroporation using the Gene Pulser Xcell electroporation system (Bio-Rad).
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